KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Cash from Financing Activities (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Cash from Financing Activities for 17 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 112.6% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$283.2 million through Dec 2025, down 29.43% year-over-year, with the annual reading at -$283.2 million for FY2025, 29.43% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $3.3 million at Bio-Rad Laboratories, up from -$52.5 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $1.2 billion in Q1 2022, with the low at -$202.7 million in Q2 2023.
  • Average Cash from Financing Activities over 5 years is -$496263.2, with a median of -$47.3 million recorded in 2021.
  • Peak annual rise in Cash from Financing Activities hit 2613.98% in 2022, while the deepest fall reached 4334.76% in 2022.
  • Over 5 years, Cash from Financing Activities stood at $4.6 million in 2021, then plummeted by 1968.28% to -$86.6 million in 2022, then tumbled by 131.62% to -$200.6 million in 2023, then surged by 86.94% to -$26.2 million in 2024, then surged by 112.6% to $3.3 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $3.3 million, -$52.5 million, and -$136.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.